ImmuCell (NASDAQ:ICCC) Announces Earnings Results, Beats Expectations By $0.05 EPS

ImmuCell (NASDAQ:ICCC) released its earnings results on Thursday. The biotechnology company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of $0.05 by $0.05, FiscalAI reports. ImmuCell had a return on equity of 2.69% and a net margin of 2.57%. The company had revenue of $8.04 million for the quarter, compared to analysts’ expectations of $5.40 million.

ImmuCell Stock Performance

ICCC traded up $0.03 during mid-day trading on Thursday, reaching $10.22. 19,294 shares of the company traded hands, compared to its average volume of 5,576. The company has a quick ratio of 2.71, a current ratio of 4.75 and a debt-to-equity ratio of 0.22. The stock has a market capitalization of $92.82 million, a P/E ratio of 127.77 and a beta of 0.61. ImmuCell has a 52-week low of $4.52 and a 52-week high of $12.10. The company’s fifty day moving average price is $10.08 and its 200-day moving average price is $9.01.

Analysts Set New Price Targets

Separately, Weiss Ratings cut ImmuCell from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, November 4th. One analyst has rated the stock with a Hold rating. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold”.

ImmuCell Company Profile

ImmuCell Corporation is a biotechnology and animal health company headquartered in Portland, Maine. The company develops, manufactures, and commercializes products designed to support the health and productivity of livestock, with a primary focus on cattle. ImmuCell’s products include FirstStep Calf Health, an on-farm diagnostic test that helps dairy and beef producers assess whether newborn calves have received adequate passive immunity from colostrum. The company also develops antibody-based products intended to help prevent or manage common diseases affecting young livestock, including neonatal calf diarrhea.